Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR002 in healthy volunteers
NCT05268198Phase 1Completed
- Sponsor
- Global Health Drug Discovery Institute
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of APR002 in coronavirus disease 2019 (COVID-19), sponsored by Global Health Drug Discovery Institute. Primary endpoint: Treatment-Emergent Adverse Events at 14 days. Started Mar 2023; status: completed.
02
Drugs
APR002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05268198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268198.